{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:01:28Z","timestamp":1781218888929,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011864","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T00:00:00Z","timestamp":1505174400000}}],"reference-count":66,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011864.pub2","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T18:21:18Z","timestamp":1505240478000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Intravesical electromotive drug administration for non-muscle invasive bladder cancer"],"prefix":"10.1002","volume":"2017","author":[{"given":"Jae Hung","family":"Jung","sequence":"first","affiliation":[{"name":"Yonsei University Wonju College of Medicine; Department of Urology; 20 Ilsan-ro Wonju Gangwon Korea, South 26426"},{"name":"University of Minnesota; Department of Urology; Minneapolis, Minnesota USA"},{"name":"Minneapolis VA Health Care System; Urology Section; Minneapolis, Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Gudeloglu","sequence":"additional","affiliation":[{"name":"Hacettepe University; Department of Urology; Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halil","family":"Kiziloz","sequence":"additional","affiliation":[{"name":"Hacettepe University; Department of Urology; Ankara Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen M","family":"Kuntz","sequence":"additional","affiliation":[{"name":"University of Florida-Jacksonville; Borland Health Sciences Library; 653-1 West Eight St. 2nd FL LRC Jacksonville Florida USA 32209"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alea","family":"Miller","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System; Urology Section; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath R","family":"Konety","sequence":"additional","affiliation":[{"name":"University of Minnesota; Department of Urology; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"Minneapolis VA Health Care System; Urology Section; Minneapolis Minnesota USA"},{"name":"University of Minnesota; Department of Urology; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,12]]},"reference":[{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Stasi","year":"2003","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD011864.pub2-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Stasi","year":"2006","journal-title":"Lancet Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"e381","DOI":"10.1016\/j.juro.2015.02.659","article-title":"Is intravesical BCG alone still the only truly effective intravesical therapy for non-muscle invasive bladder cancer?","volume":"193","author":"Stasi","year":"2015","journal-title":"Journal of Urology"},{"issue":"14","key":"10.1002\/14651858.CD011864.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"e945","DOI":"10.1016\/S1569-9056(15)60933-2","article-title":"Is intravesical BCG alone still the only truly effective intravesical therapy for high risk non muscle invasive bladder cancer?","volume":"2","author":"Stasi","year":"2015","journal-title":"European Urology Supplements"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD011864.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"4572","DOI":"10.1200\/jco.2012.30.15_suppl.4572","article-title":"Intravesical sequential BCG and electromotive mitomycin versus BCG alone in high risk non-muscle invasive bladder cancer","volume":"30","author":"Stasi","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/j.juro.2012.02.1528","article-title":"Intravesical sequential Bacillus Calmette-Guerin and electromotive mitomycin versus Bacillus Calmette-Guerin alone for stage pT1 urothelial bladder cancer","volume":"187","author":"Stasi","year":"2012","journal-title":"Journal of Urology"},{"issue":"12","key":"10.1002\/14651858.CD011864.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1016\/S1569-9056(13)61180-X","article-title":"Intravesical sequential BCG and electromotive mitomycin versus BCG alone for stage pT1 urothelial bladder cancer","volume":"1","author":"Stasi","year":"2013","journal-title":"European Urology Supplements"},{"issue":"5","key":"10.1002\/14651858.CD011864.pub2-BIB0008|cit8","first-page":"1861","article-title":"Intravesical sequential BCG and electromotive mitomycin-C versus BCG alone for stage PT1 urothelial bladder cancer","volume":"32","author":"Liberati","year":"2012","journal-title":"Anticancer Research"},{"issue":"9","key":"10.1002\/14651858.CD011864.pub2-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045%2811%2970190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"Stasi","year":"2011","journal-title":"Lancet Oncology"},{"issue":"15s","key":"10.1002\/14651858.CD011864.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1200\/jco.2010.28.15_suppl.4543","article-title":"Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle-invasive bladder cancer: a prospective randomized trial","volume":"28","author":"Stasi","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"10.1002\/14651858.CD011864.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1569-9056%2810%2960199-6","article-title":"Sigle immediate preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle invasive bladder cancer: a randomized prospective trial","volume":"9","author":"Stasi","year":"2010","journal-title":"European Urology Supplements"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"e520","DOI":"10.1016\/j.juro.2010.02.973","article-title":"Sigle preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle invasive bladder cancer: a randomized trial","volume":"183","author":"Stasi","year":"2010","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/j.juro.2012.02.1527","article-title":"Intravesical adjuvant electromotive mitomycin-C in patients with intermediate-risk non-muscle invasive bladder cancer: a randomized controlled trial","volume":"187","author":"Stasi","year":"2012","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD011864.pub2-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"e1045","DOI":"10.1016\/S1569-9056(12)61041-0","article-title":"Intravesical adjuvant electromotive drug administration (EMDA) of mitomycin-C in patients with intermediate-risk non-muscle invasive bladder cancer: a randomized controlled trial","volume":"11","author":"Stasi","year":"2012","journal-title":"European Urology Supplements"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0015|cit15","first-page":"1424","article-title":"Single preoperative intravesical instillation of electromotive mitomycin-C for primary non-muscle invasive bladder cancer: a prospective randomized trial","volume":"30","author":"Liberati","year":"2010","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0016|cit16","first-page":"1860","article-title":"Intravesical adjuvant electromotive mitomycin-C in patients with primary intermediate-risk non-muscle invasive bladder cancer: a randomized controlled trial","volume":"32","author":"Verri","year":"2012","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0017|cit17","doi-asserted-by":"crossref","unstructured":"Brausi M Campo B Pizzocaro G Rigatti P Parma A Mazza G Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative Phase II study Urology 1998 506 9","DOI":"10.1016\/S0090-4295(97)00625-0"},{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.urolonc.2006.02.007","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"24","author":"Grossman","year":"2006","journal-title":"Urologic Oncology: Seminars and Original Investigations"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0019|cit19","unstructured":"NCT01920269 Intravesical Adjuvant Electromotive Mitomycin-C (EMDA\/MMC) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01920269?term=NCT01920269&rank=1"},{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD011864.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/ajco.12070","article-title":"Minimal important differences in the EORTC QLQ-C30 in patients with advanced cancer","volume":"10","author":"Bedard","year":"2014","journal-title":"Asia Pacific Journal of Clinical Oncology"},{"issue":"3 Pt 2","key":"10.1002\/14651858.CD011864.pub2-BIB0022|cit22","first-page":"934","article-title":"Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment","volume":"153","author":"Bouffioux","year":"1995","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD011864.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD011864.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Guerin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD011864.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0026|cit26","unstructured":"Canadian Agency for Drugs and Technologies in Health The use of the electromotive drug administration system in patients with superficial bladder cancer: a review of the clinical effectiveness, safety, and cost-effectiveness. Canadian Agency for Drugs and Technologies in Health Rapid Response Report, 2014 www.ncbi.nlm.nih.gov\/pubmedhealth\/PMH0069840\/"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0028|cit28","unstructured":"Veritas Health Innovation Covidence systematic review software 2013. Available at www.covidence.org"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0029|cit29","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 9: Analysing data and undertaking meta-analyses Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011"},{"issue":"19","key":"10.1002\/14651858.CD011864.pub2-BIB0030|cit30","first-page":"4912","article-title":"Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"Stasi","year":"1999","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0031|cit31","unstructured":"Clarivate Analytics EndNote Version 7.5 2016"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0032|cit32","unstructured":"Ferlay J Soerjomataram I Ervik M Dikshit R Eser S Mathers C GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013 globocan.iarc.fr"},{"issue":"1","key":"10.1002\/14651858.CD011864.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bju.13354","article-title":"The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade\/grade 3 bladder cancer treated with Bacille Calmette-Gu\u00e9rin","volume":"118","author":"Gontero","year":"2016","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0034|cit34","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University, 2015 (developed by Evidence Prime, Inc.) Available from www.gradepro.org"},{"issue":"7651","key":"10.1002\/14651858.CD011864.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"What is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"12","key":"10.1002\/14651858.CD011864.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.jclinepi.2011.01.012","article-title":"GRADE guidelines 6. Rating the quality of evidence - imprecision","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD011864.pub2-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD011864.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0040|cit40","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011. Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0041|cit41","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing the risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0042|cit42","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/1477-7525-11-109","article-title":"Patient-reported outcomes in meta-analyses. Part 1: assessing risk of bias and combining outcomes","volume":"11","author":"Johnston","year":"2013","journal-title":"Health and Quality of Life Outcomes"},{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0045|cit45","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urologic Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"Journal of Urology"},{"issue":"7","key":"10.1002\/14651858.CD011864.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"5","key":"10.1002\/14651858.CD011864.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s00280-014-2423-y","article-title":"Intravesical mitomycin C combined with local microwave hyperthermia in non-muscle-invasive bladder cancer with increased European Organization for Research and Treatment of Cancer (EORTC) score risk of recurrence and progression","volume":"73","author":"Maffezzini","year":"2014","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"8","key":"10.1002\/14651858.CD011864.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"338.e19","DOI":"10.1016\/j.urolonc.2015.05.011","article-title":"The effect of surgical duration of transurethral resection of bladder tumors on postoperative complications: an analysis of ACS NSQIP data","volume":"33","author":"Matulewicz","year":"2015","journal-title":"Urologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4103\/0970-1591.166446","article-title":"Intravesical chemotherapy in non-muscle-invasive bladder cancer","volume":"31","author":"Porten","year":"2015","journal-title":"Indian Journal of Urology"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0052|cit52","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"5","key":"10.1002\/14651858.CD011864.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of Bacille Calmette-Gu\u00e9rin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1002\/14651858.CD011864.pub2-BIB0054|cit54","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD011864.pub2-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006885.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001986","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin in Ta and T1 bladder cancer","author":"Shelley","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003231","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","author":"Shelley","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD011864.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"Journal of Urology"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD011864.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"Journal of Urology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD011864.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.urology.2005.06.135","article-title":"High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder","volume":"66","author":"Sylvester","year":"2005","journal-title":"Urology"},{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD011864.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","article-title":"Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation?","volume":"69","author":"Sylvester","year":"2016","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD011864.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-015-0329-5","article-title":"The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer","volume":"16","author":"Driel","year":"2015","journal-title":"Current Treatment Options in Oncology"},{"issue":"9","key":"10.1002\/14651858.CD011864.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle-invasive bladder cancer - therapy options during intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Current Urology Reports"},{"issue":"3","key":"10.1002\/14651858.CD011864.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0090-4295(98)00212-X","article-title":"Long-term follow-up of an EORTC randomized prospective trial comparing intravesical Bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group","volume":"52","author":"Witjes","year":"1998","journal-title":"Urology"},{"issue":"9","key":"10.1002\/14651858.CD011864.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011864","article-title":"Intravesical electromotive drug administration for non-muscle invasive bladder cancer","author":"Gudeloglu","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011864.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T01:33:25Z","timestamp":1679880805000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011864.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,12]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011864.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,12]]}}}